[HTML][HTML] Understanding and overcoming tumor heterogeneity in metastatic breast cancer treatment
N Pasha, NC Turner - Nature cancer, 2021 - nature.com
Rational development of targeted therapies has revolutionized metastatic breast cancer
outcomes, although resistance to treatment remains a major challenge. Advances in …
outcomes, although resistance to treatment remains a major challenge. Advances in …
The implications of clonal genome evolution for cancer medicine
S Aparicio, C Caldas - New England journal of medicine, 2013 - Mass Medical Soc
Large-scale DNA sequencing of cancer genomes has provided insight into the clonality of
tumor cells, in addition to potential targets for new therapeutic approaches. This review …
tumor cells, in addition to potential targets for new therapeutic approaches. This review …
[HTML][HTML] Improved EGFR mutation detection using combined exosomal RNA and circulating tumor DNA in NSCLC patient plasma
AK Krug, D Enderle, C Karlovich, T Priewasser… - Annals of …, 2018 - Elsevier
Background A major limitation of circulating tumor DNA (ctDNA) for somatic mutation
detection has been the low level of ctDNA found in a subset of cancer patients. We …
detection has been the low level of ctDNA found in a subset of cancer patients. We …
Single cell profiling of circulating tumor cells: transcriptional heterogeneity and diversity from breast cancer cell lines
AA Powell, AAH Talasaz, H Zhang, MA Coram… - PloS one, 2012 - journals.plos.org
Background To improve cancer therapy, it is critical to target metastasizing cells. Circulating
tumor cells (CTCs) are rare cells found in the blood of patients with solid tumors and may …
tumor cells (CTCs) are rare cells found in the blood of patients with solid tumors and may …
Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer
Although antiestrogen therapies targeting estrogen receptor (ER) α signaling prevent
disease recurrence in the majority of patients with hormone-dependent breast cancer, a …
disease recurrence in the majority of patients with hormone-dependent breast cancer, a …
[HTML][HTML] The genetic basis for cancer treatment decisions
Personalized cancer medicine is based on increased knowledge of the cancer mutation
repertoire and availability of agents that target altered genes or pathways. Given advances …
repertoire and availability of agents that target altered genes or pathways. Given advances …
New insights on PI3K/AKT pathway alterations and clinical outcomes in breast cancer
SX Yang, E Polley, S Lipkowitz - Cancer treatment reviews, 2016 - Elsevier
Abstract PI3K/AKT signaling pathway plays an important role in tumorigenesis and regulates
critical cellular functions including survival, proliferation and metabolism. PIK3CA mutations …
critical cellular functions including survival, proliferation and metabolism. PIK3CA mutations …
Detection of Tumor PIK3CA Status in Metastatic Breast Cancer Using Peripheral Blood
MJ Higgins, D Jelovac, E Barnathan, B Blair… - Clinical cancer …, 2012 - AACR
Purpose: We sought to evaluate the feasibility of detecting PIK3CA mutations in circulating
tumor DNA (ctDNA) from plasma of patients with metastatic breast cancer using a novel …
tumor DNA (ctDNA) from plasma of patients with metastatic breast cancer using a novel …
Characterization of PIK3CA and PIK3R1 somatic mutations in Chinese breast cancer patients
L Chen, L Yang, L Yao, XY Kuang, WJ Zuo, S Li… - Nature …, 2018 - nature.com
Deregulation of the phosphoinositide 3-kinase (PI3K) pathway contributes to the
development and progression of tumors. Here, we determine that somatic mutations in …
development and progression of tumors. Here, we determine that somatic mutations in …
Circulating tumor cell isolation and diagnostics: toward routine clinical use
Abstract From February 7–11, 2011, the multidisciplinary Lorentz Workshop Circulating
Tumor Cell (CTC) Isolation and Diagnostics: Toward Routine Clinical Use was held in …
Tumor Cell (CTC) Isolation and Diagnostics: Toward Routine Clinical Use was held in …